{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:52:21Z","timestamp":1790016741371,"version":"4.0.1"},"reference-count":27,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2021,2,27]],"date-time":"2021-02-27T00:00:00Z","timestamp":1614384000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","award":["ESR\u201016\u201012062"],"award-info":[{"award-number":["ESR\u201016\u201012062"]}],"id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clin Experimental Allergy"],"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chronic rhinosinusitis with nasal polyps (CRSwNP) can be a severe and debilitating disease associated with significant morbidity, loss of smell, sinus pressure and asthma exacerbations. Eosinophils play a role in the majority (85%) of patients. Benralizumab, an afucosylated monoclonal antibody directed against the IL\u20105 receptor, has powerful apoptotic effects on eosinophils.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>We sought to investigate the therapeutic benefit of inhibiting the IL\u20105 receptor using benralizumab to treat severe rhinosinusitis with nasal polyps.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with severe NP (defined by endoscopic grade 5 or more out of 8) with elevated eosinophils and a history of previous surgical or endoscopic polypectomy met entry criteria and were randomized in a double\u2010blind fashion to receive 30\u00a0mg benralizumab SC or placebo. Endoscopic NP score was assessed at baseline and at treatment week 20. CT scan, SNOT\u201022 survey and UPSIT smell test score changes were also evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Thirty\u2010three patients were screened, and twenty\u2010four (n\u00a0=\u00a024) were enrolled in the study. Compared with baseline, benralizumab significantly improved NP score (\u22120.9\u00a0\u00b1\u00a00.2,\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00.004) whereas placebo did not (\u22120.3\u00a0\u00b1\u00a00.3,\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00.166). Benralizumab induced polyp size reduction compared with placebo did not reach statistical significance (\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00.103). Five of 12 benralizumab\u2010treated patients (42%) had improvements in all major outcomes (polyp score, CT, SNOT\u201022 and smell test) versus 2 out of 12 placebo (17%). The ratio of blood eosinophil count to allergen skin test positivity correlated with polyp reduction.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Benralizumab was well\u2010tolerated and compared with baseline achieved a statistically significant reduction in nasal polyp size, sinus occupancy, symptoms and improved sensation of smell for most patients (83%).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/cea.13852","type":"journal-article","created":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T23:01:30Z","timestamp":1613602890000},"page":"836-844","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":86,"title":["Benralizumab effect on severe chronic rhinosinusitis with nasal polyps (CRSwNP): A randomized double\u2010blind placebo\u2010controlled trial"],"prefix":"10.1111","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3674-4143","authenticated-orcid":false,"given":"Jody","family":"Tversky","sequence":"first","affiliation":[{"name":"The Division of Allergy and Clinical Immunology Johns Hopkins University School of Medicine Baltimore MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew P.","family":"Lane","sequence":"additional","affiliation":[{"name":"The Department of Otolaryngology Johns Hopkins University School of Medicine Baltimore MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Azar","sequence":"additional","affiliation":[{"name":"The Division of Allergy and Clinical Immunology Johns Hopkins University School of Medicine Baltimore MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,2,27]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2011.02646.x"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2011.02709.x"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/msj.20287"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.2009.03388.x"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2012.07.047"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.4193\/Rhin09.144"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.3109\/08923973.2013.811598"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.05.032"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.19330"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.12.948"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1304048"},{"issue":"29","key":"e_1_2_10_13_1","first-page":"1","article-title":"European Position Paper on Rhinosinusitis and Nasal Polyps 2020","volume":"58","author":"Fokkens WJ","year":"2020","journal-title":"Rhinology"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.4193\/Rhino10.261"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2011.07.056"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/odi.12595"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2004.04.052"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.05.044"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2012.642359"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(17)30344-2"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0194-59989770005-6"},{"issue":"4","key":"e_1_2_10_22_1","first-page":"183","article-title":"Staging in rhinosinusitus","volume":"31","author":"Lund VJ","year":"1993","journal-title":"Rhinology"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2016.12.519"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2015.07.022"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.14089"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2020.02.023"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2017.04.024"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1177\/19458924211008685"}],"container-title":["Clinical &amp; Experimental Allergy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cea.13852","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/cea.13852","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cea.13852","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T12:35:53Z","timestamp":1693398953000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/cea.13852"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,27]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["10.1111\/cea.13852"],"URL":"https:\/\/doi.org\/10.1111\/cea.13852","archive":["Portico"],"relation":{},"ISSN":["0954-7894","1365-2222"],"issn-type":[{"value":"0954-7894","type":"print"},{"value":"1365-2222","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,27]]},"assertion":[{"value":"2020-10-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-01-05","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}